Aobiome

Aobiome: Revolutionizing Healthcare with Microbiome Therapeutics

Aobiome is a clinical-stage microbiome company that is leading the way in developing innovative therapeutics for inflammatory conditions, central nervous system disorders, and other diseases. The company's proprietary product candidates are based on a strain of class-defining, auto-regulating Ammonia Oxidizing Bacteria (AOB), which is a human commensal with well-understood and well-characterized biochemical properties that are critical to human health.

The microbiome has emerged as an exciting new frontier in healthcare research, with growing evidence suggesting that the trillions of microorganisms living inside our bodies play a crucial role in maintaining our health and wellbeing. AOB is one such microbe that has been shown to have significant therapeutic potential.

At Aobiome, we believe that the application of AOB has the potential to restore critical microbial balance in patients suffering from various diseases. Our team of world-class scientists and researchers are working tirelessly to develop safe and effective therapies based on this groundbreaking technology.

Our focus areas include inflammatory conditions such as psoriasis, atopic dermatitis, acne vulgaris, rosacea; central nervous system disorders such as depression; metabolic disorders such as obesity; respiratory infections like sinusitis; gastrointestinal disorders like irritable bowel syndrome (IBS); urogenital infections like bacterial vaginosis (BV) among others.

We have made significant progress towards developing novel therapies for these indications. Our lead product candidate AO+ Restorative Mist™ harnesses live AOBs to restore skin microbiota balance by reducing inflammation caused by harmful bacteria while promoting beneficial ones. This mist can be used topically on skin or hair for various purposes including treating acne vulgaris or improving scalp health.

Another promising product candidate under development is AO-3112 which targets Inflammatory Bowel Disease (IBD). This therapy uses encapsulated live AOBs delivered orally via capsules designed specifically for targeted delivery into the gut where they can colonize and modulate gut microbiota composition thereby reducing inflammation associated with IBD.

Our approach involves using natural microbes found within our own bodies rather than synthetic drugs which often come with unwanted side effects. We believe this approach will revolutionize healthcare by providing safer more effective treatments for patients suffering from various diseases.

In conclusion, Aobiome is at the forefront of microbiome research and development aiming to bring innovative therapies based on natural microbes found within our own bodies into mainstream medicine. With its cutting-edge technology platform focused on harnessing the power of Ammonia Oxidizing Bacteria (AOB), we are confident that we will continue making significant strides towards improving patient outcomes across multiple disease areas while also contributing significantly towards advancing scientific knowledge about how these tiny organisms impact human health.